PRAX News and Press, Praxis Precision Medicines Inc. From 03/17/21

Praxis Precision Medicines (PRAX): Q4 GAAP EPS of -$0.87 misses by $0.49.Cash and cash equivalents of $296.6MPress Release For further details see: Praxis Precision Medicines EPS misses by $0.49

PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative collaboration with The Florey Institute expands pipeline via addition of 3 ASOs t...

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, tod...

Innovative collaboration to be implemented across multiple indications starting with SCN2A-DEE CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

The FDA has designated Rare Pediatric and Orphan Drug status to Praxis Precision Medicines's ([[PRAX]] +3.4%) PRAX-222, for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). as well as Rare Pediatric tag for PRAX-562 for SCN2A-DEE and SCN8A developmental and epile...

FDA grants RPD and ODD for PRAX-222 for treatment of SCN2A-DEE FDA grants RPD for PRAX-562 for treatment of SCN2A-DEE and SCN8A-DEE CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical compa...

CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today anno...

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today anno...

Praxis Precision Medicines (PRAX) drops 11% premarket in reaction to receiving comments from the FDA on the full clinical hold of its Investigational New Drug ((IND)) submission for PRAX-114 for the treatment of major depressive disorder. The IND for PRAX-114 was placed on clinical ...

- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 - CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of th...